Preliminary #usability Assessment of a Rule-Based Digital Self-Monitoring Platform for Patients With Brain Tumors Toward Digital Early Warning Systems: Pilot #feasibility Study Background: Postoperative follow-up after brain tumor surgery is typically limited to intermittent clinic visits, leaving subtle neurological or general deterioration between visits underrecognized. Digital self-monitoring platforms may help fill this gap, but evidence in neuro-oncology is scarce, particularly regarding how patient-reported symptom trajectories can feed into future data-driven early warning systems. Objective: This study aimed to evaluate the #feasibility, use patterns, and preliminary #usability of a smartphone or web-based self-monitoring system for patients after brain tumor surgery and to explore simple rule-based digital alerts as a first step toward an advanced digital early warning framework. Methods: We conducted a single-center prospective pilot study including adults discharged after brain tumor surgery who had access to a smartphone and could use a web app. Participants completed brief symptom surveys consisting of 51 binary items across 7 symptom domains, with an automatically calculated daily total score and score history visualization. #feasibility was assessed by enrollment, retention, submission counts, and submission rates. A total of 4 interpretable alert rules based on current score, short-term worsening, new-onset symptom combinations, and persistence across domains were evaluated using each patient’s last 3 submissions as the analytic unit. Clinical deterioration was defined a priori as objective decline in performance status, new neurological deficit, radiologic progression, or clinically significant laboratory changes. Rule performance metrics and bootstrap CIs were computed. #usability and acceptability were evaluated using the System #usability Scale and additional adherence-related items. Results: Of 64 enrolled patients, 30 (47%) with ≥3 submissions formed the analysis cohort (median age 57, IQR 47.2–64.5 years; n=12.9, 43% malignant tumors); 6 (20%) experienced clinical deterioration during follow-up. Patients contributed a median of 8.5 submissions (mean 19.03, SD 30.12) at 1.7 surveys per week on average, indicating sustained but heterogeneous engagement. The best-performing rule, based on net short-term score increase, achieved an area under the receiver operating characteristic of 0.88, with sensitivity 0.83, specificity 0.92, and accuracy 0.90 on the last-window dataset, outperforming rules based solely on current score or multidomain persistence. Among 23 app users who completed the System #usability Scale, the mean score was 84.0, reflecting high perceived #usability; higher-frequency users reported stronger perceived usefulness and habit-driven use. Conclusions: This pilot study demonstrates that a smartphone or web-based self-monitoring platform for patients with brain tumor is feasible and well accepted and that simple, transparent rules applied to longitudinal symptom scores show potential to capture early signals of clinical deterioration. However, given the small sample size, these predictive metrics are preliminary and require rigorous validation in larger, independent cohorts. These findings support further development of integrated digital early warning systems that combine patient-reported trajectories with clinical and physiological data to enhance postoperative neurosurgical care.

JMIR Formative Res: Preliminary #usability Assessment of a Rule-Based Digital Self-Monitoring Platform for Patients With Brain Tumors Toward Digital Early Warning Systems: Pilot #feasibility Study #DigitalHealth #HealthTech #NeuroOncology #PatientMonitoring #BrainTumor

🗓 When: June 28 – July 1, 2026
📍 Where: Salt Lake City, Utah
👉Register:
metastasis-research.org/2024/06/26/m...
#MRS2026 #MasanoriTachikawa #BloodBrainBarrier #DrugDelivery #Pharmacokinetics #Metastasis #TohokuUniversity #NeuroOncology

📚 Insights into #immunotherapy – recently published in Neuro-Oncology: Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study
👉 doi.org/10.1007/s110...
#EANOessentials #NeuroOncology #Pembrolizumab

🗳️ 𝗘𝗔𝗡𝗢 𝗘𝗹𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝟮𝟬𝟮𝟲–𝟮𝟬𝟮𝟴 𝗮𝗿𝗲 𝗼𝗽𝗲𝗻!
Shape the future of neuro-oncology by joining the #EANO Executive Board or one of our committees. We invite motivated EANO members to apply and actively contribute to our community.
🗓 Deadline: May 28, 2026
💻 Learn more: www.eano.eu

#EANOElections #NeuroOncology

🧠 Thank you for joining us at the recent #EANOYoungsters Journal Club session: INDIGO 2.0 – the next episode!
👉 Missed it or want to revisit the discussion? Watch the full recording now on YouTube: youtu.be/VboCYAtgXrY?...
We look forward to seeing you at the next session!
#NeuroOncology #EANO

🧪 𝗡𝗼𝘄 𝗼𝗽𝗲𝗻: #𝗘𝗔𝗡𝗢 𝗘𝗹𝗲𝗰𝘁𝗶𝗼𝗻𝘀 Be part of the Scientific Committee and help drive innovation and collaboration in the field. Submit your application by May 28, 2026 and get involved. Learn more 👉 www.eano.eu #NeuroOncology #braintumor #btsm

Preoperative prediction of 5-ALA fluorescence in gliomas: comparison of 7-Tesla magnetic resonance spectroscopic imaging, contrast-enhancement on MRI, and positron emission tomography - European Radiology Objectives We investigated whether metabolic ratios derived from ultra-high-field 7-T 3D-FID-CRT-MRSI can predict intraoperatively visible 5-aminolevulinic acid (5-ALA) fluorescence in gliomas and…

Integrating advanced metabolic imaging into neuro-oncologic workflows may further refine patient selection for fluorescence-guided surgery and improve intraoperative tumor targeting. 🎯"

#Neuroradiology #Glioma #MRI #Spectroscopy #NeuroOncology

buff.ly/UAWmGGL (Sara Huskic et al.)

#Glioblastoma care depends on high‑quality, integrated clinical decision‑making across the full treatment pathway. Ther Adv Med Oncol invites submissions to a special collection on clinically actionable advances in glioblastoma care.
Submission deadline: 11 Dec 2026
buff.ly/8jRyYqj
#NeuroOncology

Neuro Oncology Research Summary March 2026 - Summarized Science Summary of key Neuro Oncology publications highlighting major findings, clinical relevance, and emerging research trends.

🧠 Neuro Oncology Research Highlights - Mar 2026

• ERADECs outperform antibodies in PD-L1 degradation and tumor suppression
• STANM achieves 200-fold drug concentration increase at tumor sites
• Structural variants drive 60%+ of pediatric cancer mutations

pir.sh/pzy1bxPalv

#NeuroOncology

Meningioma Research Summary March 2026 - Summarized Science Summary of key Meningioma publications highlighting major findings, clinical relevance, and emerging research trends.

🧠 Meningioma Research Highlights - Mar 2026

• Panobinostat shows efficacy in 70% of meningioma organoids
• PD-L1 positivity flags hyperaggressive meningioma subgroup
• Molecular-morphologic classification improves radiotherapy timing

pir.sh/nKzaE7Q1Jp

#Meningioma #Neurooncology

🚨Today, April 9, 2026, at 23:59 CEST is the very last day to submit your abstract for #EANO2026. We’re very excited to see so many submissions & are looking forward to your presentations! 👉 www.eano.eu/eano2026/abs...

#Neurosurgery #NeuroOncology #RadiationOncology #AHP #nurses

💡 Recently published in "Cell Reports Medicine":
TET CpG sequence-context-specific DNA demethylation shapes progression of IDH-mutant gliomas
Open Access. Read more 🔗 t1p.de/wrciu
@cellpress.bsky.social @angelodipa.bsky.social

#EANOessentials #NeuroOncology #Oligodendrogliomas #OpenAccess

🧠 EANO Elections 2026–2028 Join the #EANO Executive Board and play a key role in shaping the future of neuro-oncology in Europe. Specialists from all disciplines are encouraged to apply. Learn more and apply by May 28, 2026 👉 www.eano.eu/about/news/n...

#EANOElections #EANO2026 #NeuroOncology

Ther Adv Med Oncol announces an open call for a Special Collection on Advances in Clinical Care for Glioblastoma.
We welcome clinically actionable research across the care pathway, from diagnostics to patient‑centered outcomes.
buff.ly/8jRyYqj
#Glioblastoma #NeuroOncology #MedicalOncology

⏰ Still working on your abstract submission for #EANO2026? Don’t panic: The submission deadline has been extended until April 9, 2026, 23:59 CEST.
eano.eu/eano2026/abs... #neurosurgery #NeuroOncology #btsm

Presented at #EANO2025, now published in Cancer Research: MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis are Clinically Relevant Across Central Nervous System Disorders
Read more: aacrjournals.org/cancerres/ar...
#EANOessentials #NeuroOncology #OpenAccess

📸 Throwback Thursday: EANO Seminars 2026 in Bucharest – multidisciplinary, patient-centred neuro-oncology and inspiring exchange across disciplines. Thank you to all contributors for an inspiring exchange!

#EANO #NeuroOncology #CNS #EANOSeminars2026 #TBT

Read the article “A case of #radiation treatment effect mimicking viable, recurrent #meningioma on #DOTATATE PET imaging” in #NeuroOncology Advances:

bit.ly/4c4lsQ2

⏰ Still 1 day to apply!
Don’t miss your chance to join the 3rd EANO School of Neuro-Oncology (2026–2028) by the EANO European Association of Neuro-Oncology.
🗓 Deadline: March 25, 2026
Apply now: www.eano.eu/school-of-ne...

#EANO #NeuroOncology #CareerDevelopment

Researchers used an oncolytic virus to kill cancer cells and draw T cells deep into glioblastoma tumours, with early trial data suggesting longer survival for some patients. Science catching up with an “untreatable” cancer. #CancerResearch #NeuroOncology #TCSC

🧠 Join the next #EANO Youngsters Journal Club
📍 INDIGO 2.0: the next episode
📅 April 7, 2026 | 16:30 CEST
Discuss latest advances in #NeuroOncology with experts & early-career researchers.
👉 Register free: bit.ly/JournalClub-...

Yesterday, we explored how the brain maintains internal time. Now we shift to another challenge: how diseases like glioblastoma and medulloblastoma disrupt neural systems. These tumors actively evade immune destruction, complicating treatment. #BrainAwarenessWeek #NeuroOncology

Excited to share our new review in Cancers on sociodemographic disparities and health-related quality of life in adults with gliomas.

mdpi.com/2072-6694/18...

#NeuroOncology #HealthEquity #BrainTumors

Three days of neuro-oncology exchange in Bucharest!
After the #EANOTumorBoard2026, the #EANOSeminars2026 continue today, bringing together young neuro-oncology professionals from across Europe.
#EANO #NeuroOncology #BrainTumors

While the neuro-oncology community is gathering in Bucharest for inspiring #EANO events, the next highlight is already on the horizon.
🔬 Be part of #EANO2026 in Rome and present your research. Submit your abstract now:
eano.eu/eano2026/abs...
#NeuroOncology #BrainTumor #BTSM

✅️ Recognize key histologic and immunohistochemical features supporting diagnosis
✅️ Identify evidence-based systemic therapy strategies across pediatric and adult medulloblastoma

#Medulloblastoma #NeuroOncology #Oncology #OncoIQ #MedicalEducation #CancerCare #OncologyTraining #CancerEducation

🙌 Insightful discussions today in Bucharest at the #EANO Tumor Board 2026. Real-world cases and expert lectures highlighted the importance of multidisciplinary collaboration in improving care for patients with #glioma.
Supported by an unrestricted educational grant from Servier. #NeuroOncology

📅 Mark your calendars! Abstract submissions for #EANO2026 are due April 2. Don’t miss your chance to showcase your #NeuroOncology research this September! 🔬 Submit now: eano.eu/eano2026/abs...

#btsm #neurosurgery #glioma #RadOnc #BrainCancer #cancernurse #AHP @jmwerner.bsky.social

🙌 Celebrating Women in Science & Medicine! On #InternationalWomensDay, we recognize the outstanding contributions of women in #NeuroOncology, research, and healthcare. EANO is proud to support and empower women in the field – today & every day. 💜 #WomenDay2026 #btsm

🧠 Recently published in Brain Pathology:
cIMPACT-NOW update 11: Proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumors
Read full article: pubmed.ncbi.nlm.nih.gov/40887057/

#EANOessentials #NeuroOncology #OpenAccess